首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
【24h】

Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients

机译:两种检测乳腺癌患者血清胸苷激酶1活性的方法的诊断和预后性能的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background: We compared two recently developed immunoassays for serum thymidine kinase 1 (TK1) activity: one manual assay (DiviTum, Biovica?) and one fully automated assay (Liaison, Diasorin?). Methods: The study included 368 women: 149 healthy blood donors (control), 59 patients with benign breast disease (BBD) and 160 patients with primary breast cancer (BC). Results: A regression analysis of the Liaison (y) and DiviTum (x) assays for all three groups yielded the equation y=3.93+0.03x (r=0.85, n=368). The r-value in BC was higher than in control and BBD (0.90 vs. 0.81 and 0.64). The correlation between the two assays for TK1 values above the cut-off was higher compared to that below (0.88 and 0.59). Breakdown of the BBD group into subgroups with proliferative and non-proliferative lesions was effective only with the measurement of TK1 with DiviTum assay (p=0.03). The TK1 activity determined preoperatively in BC patients with DiviTum and Liaison assays was significantly associated with T-stage (for both p=0.01), presence of vascular invasion (p=0.002 and p=0.02), lack of estrogen receptor (ER) (p=0.001 and p=0.01) and progesterone receptor (PR) (p=0.01 and p=0.03) expression. Only TK1 analyzed with the DiviTum assay was associated with tumor grade and molecular subtype of BC (p=0.02 and p=0.003). Multivariate Cox proportional hazards analyses demonstrated that T-stage, PR status and TK1 activity measured by both methods (DiviTum, RR=3.0, p=0.02 and Liaison, RR=3.1, p=0.01) were independent predictors of disease recurrence. Conclusions: In spite of differences observed between TK1 activity measured by the DiviTum and Liaison assays, both of them may be used for recurrence prediction in preoperative evaluation of BC patients.
机译:背景:我们比较了两种最新开发的针对血清胸苷激酶1(TK1)活性的免疫测定法:一种手动测定法(DiviTum,Biovica?)和一种全自动测定法(Liaison,Diasorin?)。方法:该研究包括368名妇女:149名健康献血者(对照),59名良性乳腺疾病(BBD)患者和160名原发性乳腺癌(BC)患者。结果:对所有三组的联络(y)和DiviTum(x)分析进行回归分析得出方程y = 3.93 + 0.03x(r = 0.85,n = 368)。 BC中的r值高于对照和BBD中的r值(0.90对0.81和0.64)。与低于临界值(0.88和0.59)相比,对于高于临界值的TK1值的两种测定之间的相关性更高。将BBD组分解为具有增生性和非增生性病变的亚组仅在用DiviTum测定法测量TK1时有效(p = 0.03)。在BC患者中用DiviTum和Liaison分析法在术前确定的TK1活性与T期(p = 0.01),是否存在血管浸润(p = 0.002和p​​ = 0.02),缺乏雌激素受体(ER)显着相关( p = 0.001和p = 0.01)和孕激素受体(PR)(p = 0.01和p = 0.03)的表达。仅用DiviTum分析法分析的TK1与BC的肿瘤等级和分子亚型有关(p = 0.02和p = 0.003)。多元Cox比例风险分析表明,两种方法(DiviTum,RR = 3.0,p = 0.02和联络,RR = 3.1,p = 0.01)测量的T期,PR状态和TK1活性是疾病复发的独立预测因子。结论:尽管通过DiviTum和Liaison分析测定的TK1活性之间存在差异,但两者均可用于BC患者术前评估的复发预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号